Efficacy of pneumococcal vaccination in adults: a meta-analysis

Background: Clinical trials and meta-analyses have produced conflicting results of the efficacy of unconjugated pneumococcal polysaccharide vaccine in adults. We sought to evaluate the vaccine's efficacy on clinical outcomes as well as the methodologic quality of the trials. Methods: We searched several databases and all bibliographies of reviews and meta-analyses for clinical trials that compared pneumococcal polysaccharide vaccine with a control. We examined rates of pneumonia and death, taking the methodologic quality of the trials into consideration. Results: We included 22 trials involving 101 507 participants: 11 trials reported on presumptive pneumococcal pneumonia, 19 on all-cause pneumonia and 12 on all-cause mortality. The current 23-valent vaccine was used in 8 trials. The relative risk (RR) was 0.64 (95% confidence interval [CI] 0.43–0.96) for presumptive pneumococcal pneumonia and 0.73 (95% CI 0.56–0.94) for all-cause pneumonia. There was significant heterogeneity between the trials reporting on presumptive pneumonia (I2 = 74%, p < 0.001) and between those reporting on all-cause pneumonia (I2 = 90%, p < 0.001). The RR for all-cause mortality was 0.97 (95% CI 0.87–1.09), with moderate heterogeneity between trials (I2 = 44%, p = 0.053). Trial quality, especially regarding double blinding, explained a substantial proportion of the heterogeneity in the trials reporting on presumptive pneumonia and all-cause pneumonia. There was little evidence of vaccine protection in trials of higher methodologic quality (RR 1.20, 95% CI 0.75–1.92, for presumptive pneumonia; and 1.19, 95% CI 0.95–1.49, for all-cause pneumonia in double-blind trials; p for heterogeneity > 0.05). The results for all-cause mortality in double-blind trials were similar to those in all trials combined. There was little evidence of vaccine protection among elderly patients or adults with chronic illness in analyses of all trials (RR 1.04, 95% CI 0.78–1.38, for presumptive pneumococcal pneumonia; 0.89, 95% CI 0.69–1.14, for all-cause pneumonia; and 1.00, 95% CI 0.87–1.14, for all-cause mortality). Interpretation: Pneumococcal vaccination does not appear to be effective in preventing pneumonia, even in populations for whom the vaccine is currently recommended.

[1]  M. Heidelberger,et al.  PREVENTION OF PNEUMOCOCCAL PNEUMONIA BY IMMUNIZATION WITH SPECIFIC CAPSULAR POLYSACCHARIDES , 1945, The Journal of experimental medicine.

[2]  C. Clancy,et al.  Does skepticism towards medical care predict mortality? , 1999, Medical care.

[3]  J. Holden,et al.  Vaccines for preventing pneumococcal infection in adults. , 2008, The Cochrane database of systematic reviews.

[4]  J. Bartlett,et al.  Bacteriology of hospital-acquired pneumonia. , 1986, Archives of internal medicine.

[5]  M. Leinonen,et al.  Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. , 1997, The American journal of medicine.

[6]  A M Zaslavsky,et al.  Racial disparity in influenza vaccination: does managed care narrow the gap between African Americans and whites? , 2001, JAMA.

[7]  A. Oxman,et al.  Clinical effectiveness of pneumococcal vaccine. Meta-analysis. , 1999, Canadian family physician Medecin de famille canadien.

[8]  J. Schwartz,et al.  The clinical effectiveness of pneumococcal vaccine in the elderly. , 1988, Annals of internal medicine.

[9]  D. Moher,et al.  The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration , 2001, Annals of Internal Medicine.

[10]  N. Waugh,et al.  Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults. , 2002, Vaccine.

[11]  P. Lumbiganon,et al.  Pneumococcal vaccination during pregnancy for preventing infant infection. , 2006, The Cochrane database of systematic reviews.

[12]  Christina C. Chang,et al.  Pneumococcal vaccines for children and adults with bronchiectasis. , 2007, The Cochrane database of systematic reviews.

[13]  E. Davies,et al.  Pneumococcal vaccines for sickle cell disease. , 2004, The Cochrane database of systematic reviews.

[14]  M. Leinonen,et al.  Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people , 1998, The Lancet.

[15]  N. French,et al.  23–valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial , 2000, The Lancet.

[16]  R. Horwitz,et al.  Adherence to treatment and health outcomes. , 1993, Archives of internal medicine.

[17]  M. Fine,et al.  Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. , 1996, JAMA.

[18]  Onchee Yu,et al.  Effectiveness of pneumococcal polysaccharide vaccine in older adults. , 2003, The New England journal of medicine.

[19]  M. Rohani,et al.  Epidemiology of Streptococcus pneumoniae infection in Malaysia , 1999, Epidemiology and Infection.

[20]  S. Bangdiwala,et al.  Racial and ethnic disparities in influenza vaccination among elderly adults , 2005, Journal of General Internal Medicine.

[21]  M. Mallaret,et al.  [Clinical trial of an antipneumococcal vaccine in elderly subjects living in institutions]. , 1985, Revue d'epidemiologie et de sante publique.

[22]  R. Adair,et al.  The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. , 1991, The New England journal of medicine.

[23]  G. Gislason,et al.  Response to pneumococcal vaccine in chronic obstructive lung disease--the effect of ongoing, systemic steroid treatment. , 2006, Vaccine.

[24]  A. Safary,et al.  Placebo controlled pneumococcal immunization in patients with bronchogenic carcinoma. , 1986, European journal of cancer & clinical oncology.

[25]  C. Aranda,et al.  Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. A pilot study. , 1987, Chest.

[26]  Schwartz Js,et al.  The Clinical Effectiveness of Pneumococcal Vaccine in the Elderly , 1988 .

[27]  J. Boissel,et al.  Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. , 2001, Vaccine.

[28]  C. Whitney.  Impact of Conjugate Pneumococcal Vaccines , 2005, The Pediatric infectious disease journal.

[29]  J. Puig-Barberà,et al.  Efectividad de la vacuna frente al neumococo en el anciano. Revisión sistemática y metaanálisis , 2002 .

[30]  J. Rubins,et al.  Magnitude, duration, quality, and function of pneumococcal vaccine responses in elderly adults. , 1998, The Journal of infectious diseases.

[31]  A. Detsky,et al.  Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. , 1994, Archives of internal medicine.

[32]  J. Puig-Barberá,et al.  [Pneumococcal vaccine effectiveness in the elderly. Systematic review and meta-analysis]. , 2002, Atencion primaria.

[33]  A. Melegaro,et al.  The 23-Valent Pneumococcal Polysaccharide Vaccine. Part I. Efficacy of PPV in the Elderly: A Comparison of Meta-Analyses , 2003, European Journal of Epidemiology.

[34]  M. Posch,et al.  Impact of Pneumococcal Vaccination on Morbidity and Mortality of Geriatric Patients: A Case-Controlled Study , 2003, Gerontology.

[35]  A. Schilder,et al.  Pneumococcal vaccines for preventing otitis media (Review) , 2004 .

[36]  A. Hall,et al.  Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence. , 2003, Lancet. Infectious Diseases (Print).

[37]  M. Egger,et al.  Bibliographic study showed improving methodology of meta-analyses published in leading journals 1993-2002. , 2007, Journal of clinical epidemiology.

[38]  Benjamin A Lipsky,et al.  Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials , 2000, BMC family practice.

[39]  Douglas G Altman,et al.  Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study , 2008, BMJ : British Medical Journal.

[40]  M. Leinonen,et al.  Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. , 1999, Vaccine.

[41]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[42]  R. Douglas,et al.  IMMUNISATION WITH A POLYVALENT PNEUMOCOCCAL VACCINE Reduction of Adult Respiratory Mortality in a New Guinea Highlands Community , 1977, The Lancet.

[43]  Anna C. Balazs,et al.  Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. , 1980, The New England journal of medicine.

[44]  P. Kaufman.  PNEUMONIA IN OLD AGE: Active Immunization Against Pneumonia with Pneumococcus Polysaccharide; Results of a Six Year Study , 1947 .

[45]  V Demicheli,et al.  Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review , 2005, The Lancet.

[46]  J. Muñoz,et al.  Clinical efficacy of anti-pneumococcal vaccination in patients with COPD , 2005, Thorax.

[47]  H. Goossens,et al.  Community acquired pneumonia in primary care , 2006, BMJ : British Medical Journal.

[48]  J. Walters,et al.  Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. , 2010, The Cochrane database of systematic reviews.

[49]  J. Leech,et al.  Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. , 1987, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[50]  A. Schilder,et al.  Pneumococcal vaccines for preventing otitis media. , 2004, The Cochrane database of systematic reviews.

[51]  R. D. Reid,et al.  Prevention of pneumococcal pneumonia by vaccination. , 1976, Transactions of the Association of American Physicians.

[52]  M. Hilleman,et al.  Protective efficacy of pneumococcal polysaccharide vaccines. , 1977, JAMA.

[53]  S. Dhami,et al.  Pneumococcal vaccine for asthma. , 2002, The Cochrane database of systematic reviews.

[54]  T. Mertens.  Estimating the effects of misclassification , 1993, The Lancet.

[55]  N. Waugh,et al.  The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomised controlled trials. , 2004, Vaccine.

[56]  I. Chalmers.  Comparing like with like: some historical milestones in the evolution of methods to create unbiased comparison groups in therapeutic experiments. , 2001, International journal of epidemiology.

[57]  D. Fedson.  Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: another view of the evidence. , 2003, The Lancet. Infectious diseases.

[58]  H. Campbell,et al.  Serotypes/groups distribution and antimicrobial resistance of invasive pneumococcal isolates: implications for vaccine strategies , 2000, Epidemiology and Infection.

[59]  Z. Ballas,et al.  Anti-pneumococcal antibody response in normal subjects: a meta-analysis. , 1996, The Journal of allergy and clinical immunology.

[60]  A. Cross,et al.  Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study. , 1986, The New England journal of medicine.

[61]  P. Kaufman.  STUDIES ON OLD AGE PNEUMONIA: II. PROPHYLACTIC EFFECT OF PNEUMOCOCCUS POLYSACCHARIDE AGAINST PNEUMONIA , 1941 .

[62]  R. Gibbons,et al.  Coronary Revascularization: New Evidence, New Challenges , 2007, Annals of Internal Medicine.

[63]  K. Westling.  National Institute of Allergy and Infectious Diseases, NIH: Volume 1: Frontiers in Research , 2008 .

[64]  Tamara Pilishvili,et al.  Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. , 2005, JAMA.

[65]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[66]  R. Pebody,et al.  Pneumococcal polysaccharide vaccine uptake in England, 1989-2003, prior to the introduction of a vaccination programme for older adults. , 2006, Journal of public health.